Improved diagnosis of citrin deficiency by newborn screening using a molecular second-tier test

Background: Citrin deficiency is an autosomal recessive disorder caused by variants of the SLC25A13 gene. Al-though newborn screening (NBS) provides an opportunity for its early diagnosis and treatment, citrin deficiency detection rates remain lower than those estimated.Methods: Before 2018, NBS for citrin deficiency was based on citrulline levels alone. In June 2018, a second-tier molecular test was implemented to detect 11 common variants of the SLC25A13 gene and improve the NBS de-tection rates. This study compares the incidence rates and costs before and after the second-tier implementation.Results: Prior to 2018, five subjects were diagnosed via NBS, and 12 of 555,449 newborns screened were missed. In comparison, 11 subjects were diagnosed out of 198,071 newborns screened after 2018, and there were no false-negatives. The citrin deficiency detection rate increased from 1/32,673 to 1/18,006 after the second-tier test was implemented, with only a minimal increase in the total cost. The number of false-positive in our cohort was tolerable. Subjects with citrin deficiency may present with borderline elevated citrulline levels; these can re-main slightly elevated or increase considerably on retest. Four patients (80%) detected prior to second-tier testing and six patients (55%) detected after it was implemented were identified based on the citrulline levels alone. However, at the time of second blood sampling, the normal citrulline level of five subjects did not exclude a citrin deficiency diagnosis.Conclusions: Our study shows that it is vital and cost-effective to employ second-tier molecular testing to improve the detection of citrin deficiency by NBS.(c) 2022 Elsevier Inc. All rights reserved.

Automated summary

This study demonstrates the importance and cost-effectiveness of employing second-tier molecular testing to improve the detection rate of citrin deficiency by newborn screening.